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schemic heart disease is the leading cause of morbidity and
ortality in the U.S. and industrialized countries (1). In
cute myocardial infarction, tissue loss leads to hemody-
amic stress followed by compensatory left ventricular
ypertrophy and dilation (2). In recent years, several studies
ave shown that transplantation of skeletal myoblasts (3),
one marrow cells (4,5), mesenchymal stem cells (6), endo-
helial progenitor cells (7), cardiac resident stem cells
8–10), and embryonic stem cell derivatives (11–13) can
ccelerate the myocardial regenerative process. The mech-
nism(s) may be related to stem cells secreting multiple
ngiogenic factors, providing a mechanical scaffold, and/or
ecruiting other beneficial cells to the ischemic territory
14). However, results from more recent large randomized
linical trials related to circulating progenitor cells (the
OPCARE-CHD [Transplantation of Progenitor Cells
nd Recovery of LV Function in Patients with Chronic
schemic Heart Disease] trial) (15), bone marrow cells (the
STAMI [Autologous Stem-Cell Transplantation in
cute Myocardial Infarction] trial) (16), and skeletal myo-
lasts (the MAGIC [Myoblast Autologous Grafting in
schemic Cardiomyopathy] trial) (17) have yielded no sig-
ificant results. The cause for this disappointment could be
ue to suboptimal delivery techniques, insufficient engraft-
ent, acute donor cell death, and/or other unknown causes.
See page 1652
Thus, despite the exciting promise of stem cell therapy,
any gaps still exist in the understanding of stem cell
iology. This sentiment is reflected by a National Heart,
ung, and Blood Institute workshop on stem cell transplan-
ation, which stated: “It is of critical importance to adopt
tandard assays. . .to determine whether grafted cells func-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Department of Medicine (Cardiology) and Radiology, Molecularl
maging Program at Stanford, Stanford University School of Medicine, Stanford,
alifornia.ion in a predictable way. . .and to have molecular markers
hat would determine the nature of the engrafted cells and
heir progeny” (18). Therefore, the development of imaging
trategies that can monitor stem cell survival, proliferation,
nd migration will represent a significant advance in the
tem cell field.
ifferent Imaging Modalities
o date, the majority of studies on stem cell fate have relied on
x vivo analysis such as histologic staining for green fluorescent
rotein or -galactosidase. To understand cell fate in vivo,
oninvasive techniques must be developed. The first approach
s to directly label cells with radioactive tracers (e.g., 111Indium
r 18F-FDG) and monitor cell trafficking by a gamma camera
r single-photon emission computed tomography (SPECT) or
ositron emission tomography (PET) imaging. The advan-
ages here are the high detection sensitivity of nuclear imaging
echniques and possible immediate translation to clinical prac-
ice, as most of the radiotracers are already in clinical use. For
xample, Hofmann et al. (19) isolated bone marrow cells from
atients with acute myocardial infarction and radiolabeled
hem with 18F-FDG. After intracoronary delivery of 18F-
DG–labeled CD34 enriched cells, they found that 14% to
9% of the total activity was detected in the infarcted myocar-
ium after 1 h. However, the short half-lives of 18F (110 min)
nd most other radioisotopes limit these type of studies to less
han 1 to 3 days. The second approach is to label cells with iron
articles and track cell fate by magnetic resonance imaging
MRI) (20). The main advantage here is MRI’s capacity for
igh anatomic resolution of the sites where cells were injected.
owever, MRI is unable to distinguish viable from nonviable
ells, as iron particles may be retained by living cells, dead cells,
r scavenger cells (21–23). Thus, the robust cell signals that
ersist out to 8 weeks seen in previous studies most likely do
ot represent viable cells (6). The third approach is based on
he transfer of various reporter gene constructs into stem cells
ia a viral or nonviral vector (24). As described in Figure 1, this
imple but elegant approach can truly characterize the survival,
roliferation, and death of transplanted cells. The same ap-
roach was employed by Terrovitis et al. (25) in this issue of
he Journal to image the fate of transplanted rat cardiac-derived
tem cells (rCDCs), also known as resident cardiac stem cells,
sing a combined SPECT and PET imaging approach.
ET and SPECT Imaging of rCDCs
errovitis et al. (25) examined the use of a sodium iodide
ymporter (NIS) reporter gene to track the fate of transplanted
CDCs. The NIS is normally expressed in the thyroid, stom-
ch, choroid plexus, and salivary gland, but not in the heart.
he reporter probes used were technetium 99m and iodine 124
or SPECT and PET imaging, respectively. In addition,
hallium 201 (or ammonia 13) radiotracers were used as a road
ap for myocardial delineation. Their results showed thatentiviral transduction of rCDCs with the NIS reporter gene
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Molecular Imaging November 11, 2008:1661–4id not adversely affect cell viability, proliferation, cardiogenic
otential, and angiogenic capacity. After left anterior descend-
ng coronary artery ligation of the rat heart, rCDCs (1  106
4 106) were injected intramyocardially. The rCDCs were
etected by SPECT imaging on days 1, 3, and 6 post-injection
ut not on day 10 (imaging contrast ratios were 452  29%,
96  71%, 131  66%, and 1.1  14%, respectively).
nterestingly, the imaging contrast ratio obtained by PET was
ess optimal, suggesting a potential limitation of iodine 124 as
reporter probe for NIS.
Importantly, the imaging results indicate that NIS can be
sed for longitudinal stem cell tracking. They also suggest that
he majority of transplanted cells will die within the first 2
eeks, as has been shown previously by other investigators
sing serial terminal deoxynucleotidyl transferase-mediated
UTP-biotin nick end labeling staining (26), TaqMan poly-
erase chain reaction of male-specific Sry gene (27), and
eporter gene imaging (28). Using real-time polymerase chain
eaction, the authors also found that 13.2  3.6% of the
njected cells were retained on day 1 and 2.8  1.8% at day 8
fter injection. This biological phenomenon begs the questions
f why a cell type (i.e., rCDCs), which can proliferate so
obustly in vitro, tends to die off so acutely after transplanta-
Figure 1 Conceptual Basis of Reporter Gene and Reporter Prob
In this study, a self-inactivating lentivirus was used to stably transduce rat cardiac
symporter (NIS) reporter gene is constitutively expressed. However, one can also a
Nkx2.5) promoters. The reporter gene/reporter probe interactions can be NIS/tec
here, or firefly luciferase/D-luciferin (bioluminescence), green fluorescence prot
ferrin receptor/iron oxide particles (magnetic resonance imaging), as in other p
the heart, 3 scenarios can happen. If the cells survive and are functionally act
radioactive reporter probes (injected into the animal before scan) to generate d
on to daughter cells, and the corresponding imaging signals will increase in int
cells. mRNA  messenger ribonucleic acid.ion, as well as whether significant “myocardial regeneration” ieading to functional improvement can indeed be achieved
sing resident cardiac stem cells (or any stem cell type) in future
linical trials. Given that the degree of cell engraftment can
ary considerably within the animal cohorts, another area of
nterest would have been to correlate the survival of rCDCs
ith the functional changes in individual animals. However,
his question was not addressed in this study.
Overall, Terrovitis et al. (25) should be congratulated for
erforming a meticulous study on the role of NIS reporter
ene imaging for tracking stem cell therapy. The NIS
rovides another alternative reporter gene to the more
ommonly used herpes simplex virus thymidine kinase
HSVtk). Because NIS is an endogenous mammalian gene,
t is expected to be less immunogenic compared with
SVtk (although a newer generation of human-derived
onimmunogenic mitochondrial thymidine kinase type 2
eporter gene has now been developed [29]). However,
ore detailed studies of the potential adverse effects of NIS
n cellular characteristics (beyond the cell proliferation and
iability data provided here) will need to be conducted in the
uture, perhaps similar to what have been done for HSVtk
eporter gene using genomics (30) and proteomics (31)
nalysis. Finally, as the authors pointed out, the feasibility of
aging for Tracking Stem Cell Fate In Vivo
d stem cells. The cytomegalovirus promoter used to drive the sodium iodide
ther promoter systems such as inducible (e.g., Tet-on) or tissue-specific (e.g.,
m 99m (for single-photon emission computed tomography imaging), as shown
uorescence), HSVtk/18F-FHBG (positron emission tomography), and trans-
sly published studies. After injection of genetically modified stem cells into
nscription and translation lead to reporter proteins, which interact with the
able imaging signals. If the cells proliferate, the reporter gene will be passed
. However, if cells are apoptotic or dead, there will be no signals from thosee Im
-derive
dopt o
hnetiu
ein (fl
reviou
ive, tra
etect
ensitymaging NIS in a large animal model needs to be demon-
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November 11, 2008:1661–4 Molecular Imagingtrated before definitive conclusions about clinical translat-
bility can be drawn.
maging to Address Biological
uestions of Stem Cell Therapy
esides this elegant report, it is worth pointing out that
everal recent studies have used the reporter gene imaging
pproach (Fig. 1) to elucidate stem cell fate and function
n vivo. Cao et al. (32) injected mouse embryonic stem
ells stably transfected with a trifusion reporter gene
firefly luciferase, red fluorescent protein, and HSVtk) in
he rodent heart to demonstrate multimodality imaging
f cell survival, cell proliferation, and ablation of cell
isbehavior. Similarly, Gyongyosi et al. (33) injected
orcine mesenchymal stem cells stably transfected with a
ariant of the trifusion reporter gene into the pig heart
nd performed clinical PET imaging to document cellu-
ar persistence at 10 days post-delivery. Rodriguez-Porcel
t al. (34) showed the feasibility of quantifying regional
yocardial transgene expression in a pig model with
linical PET/computed tomographic imaging by using
ndomyocardial catheter delivery of adenovirus carrying
he HSVtk reporter gene. Using a transgenic mouse
odel that stably expresses firefly luciferase and green
uorescent protein, Sheikh et al. (35) provided insights
nto the “spatiotemporal kinetics” of how bone marrow
ells can home in on ischemic hearts after intravenous
elivery. In a follow-up study, van der Bogt et al. (36)
erformed head-to-head comparisons of the post-
ntramyocardial transplantation survival and efficacy of
one marrow cells, skeletal myoblasts, and mesenchymal
tem cells derived from these colored transgenic mice.
inally, Hung et al. (37) showed that mouse embryonic
tem cells delivered into the normal (remote) zone have
etter cell viability compared with that seen with injec-
ions in the intrainfarction and peri-infarction zones.
onclusions
espite the potential promise of cardiac stem cell therapy,
any fundamental questions have yet to be answered. These
nclude the following issues: 1) What are the molecular and
ellular mechanisms of myocardial improvement? 2) What
re the optimal cell type, delivery technique, and cell dosage
or therapy? 3) How well do transplanted cells survive,
ntegrate, and proliferate in the target organ? 4) What is the
ong-term fate of transplanted cells—that is, do they engraft
r transdifferentiate (or both)? 5) Can these issues be
xamined via noninvasive imaging rather than invasive
iopsy or post-mortem histology? From the studies high-
ighted in the previous text, it is becoming clear that
olecular imaging will play an ever growing role in answer-
ng these questions. It is also quite heartening to see how a
eld that was originally developed by our oncology col-
eagues to track cancer gene/cell therapy (38,39) has now
radually gained acceptance by the cardiovascular commu-ity over the past 5 years. The challenge in the next 5 years
ill be to implement clinical molecular imaging to help
ulfill the promise of cardiac stem cell therapy, as well as to
esolve the disappointments and controversies surrounding
he field.
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